


		EMLc	ATC codes: L01CA02
Indication	Rhabdomyosarcoma primary site	ICD11 code: 2C25.Z	
INN	Vincristine		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate) ; 5 mg in vial (vincristine sulfate) ; 1 mg per mL in vial (vincristine sulfate) ; 2 mg per 2 mL in vial (vincristine sulfate)		
EML status history	First added in 2015 (TRS 994) Changed in 2021 (TRS 1035)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more about patents . 		
Tags	Cancer		
Wikipedia	Vincristine 		
DrugBank	Vincristine 		

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1mg/mL and 2 mg/2mL) to the EML and EMLc.

[Expert Committee report](#) 

